Home About us Contact us Sitemap | Sitemap follow us at twitter Skype Account : msdoit.com Online Chat | | TODAY : Thursday,4 March , 2018
Search :   
  Home » » Videos » MRF 008

MRF 008

The Myelin Repair Foundation (MRF) is partnering with the National Institutes of Health (NIH) to conduct a clinical trial on a potential therapeutic that may protect and repair myelin in multiple sclerosis (MS) patients.

Protect the brain.
MRF investigators found that this therapeutic—an FDA-approved drug to treat hypertension—may be “neuroprotective.” That is, unlike current MS therapies which all suppress the immune system, MRF-008 may help protect myelin-producing cells (oligodendrocytes) in the brain from damage.  
Advance next-generation treatments. The MRF-008 clinical trial represents a game-changing opportunity for the MRF and its supporters to help develop next-generation MS therapeutics. Instead of targeting the immune system, such therapeutics will protect and repair myelin—with the potential to transform the lives of MS patients around the world.

::Relation Pages

MRF-008 MRF-008 MRF 008 None None None None None MRF-008